0000000000659793

AUTHOR

Claus Neurohr

showing 4 related works from this author

Coil embolisation for massive haemoptysis in cystic fibrosis.

2021

IntroductionMassive haemoptysis is a life-threatening event in advanced cystic fibrosis (CF) lung disease with bronchial artery embolisation (BAE) as standard of care treatment. The aim of our study was to scrutinise short-term and long-term outcomes of patients with CF and haemoptysis after BAE using coils.MethodsWe carried out a retrospective cohort study of 34 adult patients treated for massive haemoptysis with super selective bronchial artery coil embolisation (ssBACE) between January 2008 and February 2015. Embolisation protocol was restricted to the culprit vessel(s) and three lobes maximum. Demographic data, functional end-expiratory volume in 1 s in % predicted (FEV1% pred.) and bod…

Pulmonary and Respiratory MedicineAdultmassive haemoptysismedicine.medical_specialtyHemoptysisCystic FibrosisMedizinBronchial ArteriesCulpritCystic fibrosisDiseases of the respiratory systemmedicine.arterymedicineHumansIn patient22181506Coil embolizationRetrospective StudiesRC705-779business.industryRRetrospective cohort studymedicine.diseaseEmbolization TherapeuticSurgeryMedicineSputummedicine.symptomBronchial arterybusinessBody mass indexBMJ open respiratory research
researchProduct

Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension:A Double-Blind Placebo-controlled Clinical Trial

2020

Rationale: Oral treprostinil improves exercise capacity in patients with pulmonary arterial hypertension (PAH), but the effect on clinical outcomes was unknown.\ud \ud Objectives: To evaluate the effect of oral treprostinil compared with placebo on time to first adjudicated clinical worsening event in participants with PAH who recently began approved oral monotherapy.\ud \ud Methods: In this event-driven, double-blind study, we randomly allocated 690 participants (1:1 ratio) with PAH to receive placebo or oral treprostinil extended-release tablets three times daily. Eligible participants were using approved oral monotherapy for over 30 days before randomization and had a 6-minute-walk dista…

MaleAdministration OralOral treprostinilCritical Care and Intensive Care MedicinePulmonary arterial hypertension[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractcombination therapyoralepoprostenol0302 clinical medicinepulmonary arterial hypertensionmiddle agedClinical endpointdouble-blind methodMESH: Double-Blind MethodFamilial Primary Pulmonary Hypertension030212 general & internal medicinehumansMESH: AgedMESH: Middle AgedEpoprostenol/analogs & derivativesadultHazard ratioMiddle Aged[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciencesantihypertensive agents3. Good healthagedfemaleMESH: Young Adultoral treprostinilMESH: Administration Oralyoung adultFemalePulmonary Arterial Hypertension/drug therapymedicine.drugAdultPulmonary and Respiratory MedicineMESH: Pulmonary Arterial Hypertensionmedicine.medical_specialtyRandomizationAdolescentclinical study; combination therapy; oral treprostinil; pulmonary arterial hypertension; sequential therapy; administration oral; adolescent; adult; aged; antihypertensive agents; double-blind method; epoprostenol; female; humans; male; middle aged; placebos; pulmonary arterial hypertension; young adultSequential therapyMESH: PlacebosMESH: EpoprostenolLower riskPlaceboadministrationClinical studyYoung Adult03 medical and health sciencesDouble-Blind Method[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmaleInternal medicineplacebosmedicineHumansCombination therapyAdverse effectPlacebos/therapeutic useAgedMESH: AdolescentPulmonary Vascular DiseaseMESH: Antihypertensive AgentsMESH: Humanssequential therapybusiness.industryMESH: AdultOriginal Articlesclinical studyMESH: MaleClinical trial030228 respiratory systemadolescentAntihypertensive Agents/administration & dosagebusinessMESH: FemaleTreprostinil
researchProduct

Quality of Life 3 and 12 Months Following Acute Pulmonary Embolism

2021

BACKGROUND Few data are available on the long-term course and predictors of quality of life (QoL) following acute pulmonary embolism (PE). RESEARCH QUESTION What are the kinetics and determinants of disease-specific and generic health-related QoL 3 and 12 months following an acute PE? STUDY DESIGN AND METHODS The Follow-up after Acute Pulmonary Embolism (FOCUS) study prospectively followed up consecutive adult patients with objectively diagnosed PE. Patients were considered for study who completed the Pulmonary Embolism Quality of Life (PEmb-QoL) questionnaire at predefined visits 3 and 12 months following PE. The course of disease-specific QoL as assessed using the PEmb-QoL and the impact …

Pulmonary and Respiratory Medicinemedicine.medical_specialtybusiness.industryVisual analogue scalePatient-centered outcomesCritical Care and Intensive Care Medicinemedicine.diseasehumanitiesPulmonary embolismClinical trialQuality of lifeInterquartile rangeInternal medicineMedicineCardiology and Cardiovascular MedicinebusinessCohort studyCardiopulmonary diseaseChest
researchProduct

S2K-Leitlinie zur Diagnostik und Therapie der idiopathischen Lungenfibrose

2013

Die idiopathische pulmonale Fibrose (IPF) ist eine schwerwiegende und in der Regel zum Tod fuhrende Erkrankung, die bisher nur unzureichend behandelt werden kann. Empfehlungen zur Diagnostik und Therapie wurden erstmals im ATS-ERS-Statement im Jahr 2000 publiziert 1 . Seither haben sich die diagnostischen Standards geandert und es liegen zahlreiche Therapiestudien zu diesem Krankheitsbild vor, die es erforderlich machten, die bestehenden Empfehlungen zu uberarbeiten und eine wissenschaftlich begrundete Leitlinie zu erstellen. Diese wurde von einer internationalen Expertengruppe in den Jahren 2006 – 2010 erarbeitet und publiziert 2 . Die folgenden Ausfuhrungen beinhalten eine Ubersetzung wes…

Pulmonary and Respiratory MedicineGynecologymedicine.medical_specialtybusiness.industryMedizinMedicineGuidelinebusiness
researchProduct